Get the Stockscreener App
0.8687
9.60%
-0.0923
After Hours:
.89
0.0213
+2.45%
Moleculin Biotech Inc stock is traded at $0.8687, with a volume of 333.02K.
It is down -9.60% in the last 24 hours and down -24.46% over the past month.
See More
Previous Close:
$0.961
Open:
$0.92
24h Volume:
333.02K
Relative Volume:
0.07
Market Cap:
$11.56M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0568
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
-17.27%
1M Performance:
-24.46%
6M Performance:
-64.69%
1Y Performance:
-83.45%
1-Day Range:
$0.85
$0.9497
1-Week Range:
$0.85
$1.0602
52-Week Range:
$0.3975
$5.91
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.8687 | 11.56M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire
Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener
Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan
Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN
What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World
Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World
Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN
Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World
Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq
H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com India
Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus
Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World
Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com
Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Moleculin Biotech Shares Corporate Presentation Update - TipRanks
FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan
Promising Advancements in Moleculin Biotech’s Annamycin Pivotal Trial Drive Buy Rating and $8 Price Target - TipRanks
Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Moleculin Biotech, Inc. SEC 10-K Report - TradingView
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire
Moleculin Biotech Prepares to Unveil Critical 2024 Financial Performance - StockTitan
Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - PR Newswire
5 Major Growth Catalysts: Moleculin Biotech CEO Reveals 2025 Strategic Roadmap - Stock Titan
Moleculin to Present at the 37th Annual ROTH Conference - Quantisnow
Moleculin to Present at the 37th Annual ROTH Conference -March 10, 2025 at 08:46 am EDT - Marketscreener.com
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - GuruFocus.com
Soft Tissue Sarcoma Market on Track for Major Expansion by 2032, According to DelveInsight | Moleculin Biotech - openPR
Moleculin Announces Additional Annamycin Patent Allowances to En - GuruFocus.com
Moleculin Biotech Inc Announces Additional Annamycin Patent Allowances To Enhance Global Exclusivity - Marketscreener.com
Moleculin Biotech to be granted new patents for Annamycin - TipRanks
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - PR Newswire
What is HC Wainwright’s Forecast for MBRX Q4 Earnings? - Defense World
StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Receives Positive FDA Guidance for Acceleration of its - GuruFocus.com
Moleculin Biotech’s (MBRX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):